Harold Schaaff
@Soleus Capital Management, L.p.
Latest period2024 - Q3ReportedManaged Assets$1.291BTotal holdings87
Assets growth rate13.9%Assets growth rate (2-Q avg)-0.97%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Soleus Capital Management, L.p.'s 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 87 positions.
Assets under management
The assets under management (AUM) of Soleus Capital Management, L.p. over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.291B in assets, with a quarterly growth rate of 13.9% and a 2-quarter average growth rate of -0.97%. The portfolio is managed by Harold Schaaff, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
TGTXTg Therapeutics Inc
| 4.6% | $59.283M 2.535M shares@ $23.4 avg price | Decreased -30.47% |
AXGNAxogen Inc
| 3.27% | $42.143M 3.006M shares@ $14.03 avg price | Decreased -9.07% |
UTHRUnited Therapeutics Corp Del
| 2.83% | $36.514M 101,894 shares@ $358.36 avg price | Decreased -27.98% |
RVMDRevolution Medicines Inc
| 2.48% | $31.953M 704,584 shares@ $45.35 avg price | Decreased -17.7% |
SRDXSurmodics Inc
| 1.92% | $24.73M 637,698 shares@ $38.78 avg price | Decreased -18.42% |
NRIXNurix Therapeutics Inc
| 1.86% | $23.949M 1.066M shares@ $22.48 avg price | Decreased -48.15% |
CSTLCastle Biosciences Inc
| 1.47% | $18.89M 662,332 shares@ $28.53 avg price | Decreased -22.4% |
BGNEBeigene Ltd
| 1.44% | $18.578M 82,750 shares@ $224.52 avg price | Decreased -39.9% |
EOLSEvolus Inc
| 1.31% | $16.81M 1.038M shares@ $16.2 avg price | Decreased -9.92% |
ALNYAlnylam Pharmaceuticals Inc
| 1.27% | $16.337M 59,400 shares@ $275.03 avg price | Decreased -17.15% |